Alan Wilhelm

631 total citations
22 papers, 388 citations indexed

About

Alan Wilhelm is a scholar working on Molecular Biology, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Alan Wilhelm has authored 22 papers receiving a total of 388 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 12 papers in Oncology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Alan Wilhelm's work include HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Cancer therapeutics and mechanisms (7 papers). Alan Wilhelm is often cited by papers focused on HER2/EGFR in Cancer Research (11 papers), Monoclonal and Polyclonal Antibodies Research (11 papers) and Cancer therapeutics and mechanisms (7 papers). Alan Wilhelm collaborates with scholars based in United States and Netherlands. Alan Wilhelm's co-authors include Yelena Kovtun, Ravi Chari, Nicholas C. Yoder, Chen Bai, Lauren Harvey, Jan Pinkas, Erin K. Maloney, Sharlene Adams, Charlene A. Audette and Victor S. Goldmacher and has published in prestigious journals such as Blood, Cancer Research and Journal of Allergy and Clinical Immunology.

In The Last Decade

Alan Wilhelm

21 papers receiving 372 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Wilhelm United States	9	273	154	128	104	47	22	388
Gregory E. Jones United States	8	463 1.7×	350 2.3×	188 1.5×	106 1.0×	64 1.4×	15	622
Rassol Laleau United States	4	164 0.6×	104 0.7×	86 0.7×	73 0.7×	32 0.7×	6	245
Gabriel N. Waterman United States	7	187 0.7×	96 0.6×	118 0.9×	178 1.7×	60 1.3×	8	310
Patrick H. van Berkel United Kingdom	9	393 1.4×	181 1.2×	112 0.9×	26 0.3×	96 2.0×	35	496
Ivica Fucek Germany	10	418 1.5×	304 2.0×	176 1.4×	103 1.0×	301 6.4×	28	593
Turner Kufe United States	6	164 0.6×	40 0.3×	216 1.7×	128 1.2×	148 3.1×	7	368
Leanne Lanieri United States	7	179 0.7×	137 0.9×	86 0.7×	17 0.2×	33 0.7×	17	286
Amelia M. Huehls United States	10	488 1.8×	144 0.9×	395 3.1×	55 0.5×	166 3.5×	15	704
Donna LeBherz United States	6	131 0.5×	186 1.2×	92 0.7×	48 0.5×	111 2.4×	8	326
Bryan Wong United States	11	153 0.6×	34 0.2×	201 1.6×	61 0.6×	60 1.3×	20	431

Countries citing papers authored by Alan Wilhelm

Since Specialization

Citations

This map shows the geographic impact of Alan Wilhelm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Wilhelm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Wilhelm more than expected).

Fields of papers citing papers by Alan Wilhelm

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Wilhelm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Wilhelm. The network helps show where Alan Wilhelm may publish in the future.

Co-authorship network of co-authors of Alan Wilhelm

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Wilhelm. A scholar is included among the top collaborators of Alan Wilhelm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Wilhelm. Alan Wilhelm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Heath, Jack, Alan Wilhelm, David P. Waterman, et al.. (2023). Prime Editing Efficiently and Precisely Corrects Causative Mutation in Chronic Granulomatous Disease, Restoring Myeloid Function: Toward Development of a Prime Edited Autologous Hematopoietic Stem Cell Therapy. Blood. 142(Supplement 1). 7129–7129. 8 indexed citations

Pomeroy, Emily J., Andrew V. Anzalone, Kanut Laoharawee, et al.. (2023). Multiplex Prime Editing and PASSIGE TM for Non-Viral Generation of an Allogeneic CAR-T Cell Product. Blood. 142(Supplement 1). 4803–4803. 7 indexed citations

Yoder, Nicholas C., Chen Bai, Wayne C. Widdison, et al.. (2019). A Case Study Comparing Heterogeneous Lysine- and Site-Specific Cysteine-Conjugated Maytansinoid Antibody-Drug Conjugates (ADCs) Illustrates the Benefits of Lysine Conjugation. Molecular Pharmaceutics. 16(9). 3926–3937. 30 indexed citations

Bai, Chen, Alan Wilhelm, Erin K. Maloney, et al.. (2019). Site-Specific Conjugation of the Indolinobenzodiazepine DGN549 to Antibodies Affords Antibody–Drug Conjugates with an Improved Therapeutic Index as Compared with Lysine Conjugation. Bioconjugate Chemistry. 31(1). 93–103. 20 indexed citations

Archer, Katie E., James R. Woods, Luke Harris, et al.. (2019). Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1211–1215. 9 indexed citations

Archer, Katie E., Alan Wilhelm, Nicholas C. Yoder, et al.. (2019). Effect of Linker Stereochemistry on the Activity of Indolinobenzodiazepine Containing Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1193–1197. 11 indexed citations

Archer, Katie E., Erin K. Maloney, Olga Ab, et al.. (2019). Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs). Bioorganic & Medicinal Chemistry Letters. 29(17). 2455–2458. 5 indexed citations

Archer, Katie E., Luke Harris, Erin K. Maloney, et al.. (2019). Optimizing Lysosomal Activation of Antibody–Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers. Molecular Pharmaceutics. 16(12). 4817–4825. 33 indexed citations

Kovtun, Yelena, Gregory E. Jones, Sharlene Adams, et al.. (2018). A CD123-targeting antibody-drug conjugate, IMGN632, designed to eradicate AML while sparing normal bone marrow cells. Blood Advances. 2(8). 848–858. 129 indexed citations

10.

Adams, Sharlene, Meghan Kelly, Alan Wilhelm, et al.. (2017). IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively with Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro and Prolonged Survival In Vivo. Blood. 130. 1357–1357. 6 indexed citations

11.

Miller, Michael L., Nathan Fishkin, Wěi Li, et al.. (2016). A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity. Molecular Cancer Therapeutics. 15(8). 1870–1878. 65 indexed citations

12.

Adams, Sharlene, Alan Wilhelm, Lauren Harvey, et al.. (2016). IMGN632: A CD123-Targeting Antibody-Drug Conjugate (ADC) with a Novel DNA-Alkylating Payload, Is Highly Active and Prolongs Survival in Acute Myeloid Leukemia (AML) Xenograft Models. Blood. 128(22). 2832–2832. 13 indexed citations

13.

Kovtun, Yelena, Gregory E. Jones, Charlene A. Audette, et al.. (2016). A CD123-Targeting Antibody-Drug Conjugate (ADC), IMGN632, Designed to Eradicate Acute Myeloid Leukemia (AML) Cells While Sparing Normal Bone Marrow Cells. Blood. 128(22). 768–768. 5 indexed citations

14.

Vitharana, Dilrukshi, Alan Wilhelm, Luke Harris, et al.. (2016). Abstract 2965: In vitro and in vivo activity of a site-specific SeriMab antibody-drug conjugate (ADC) using an indolino-benzodiazepine DNA-alkylating agent. Cancer Research. 76(14_Supplement). 2965–2965. 1 indexed citations

15.

Lai, Katharine C., Xiuxia Sun, Rassol Laleau, et al.. (2015). Abstract 4504: Plasma pharmacokinetics and tumor accumulation in mice of IMGN779, an antibody-drug conjugate for acute myeloid leukemia. Cancer Research. 75(15_Supplement). 4504–4504. 1 indexed citations

16.

Whiteman, Kathleen R., Charlene A. Audette, Andre Dandeneau, et al.. (2014). Abstract 2644: Antibody-drug conjugates (ADCs) with a novel DNA-alkylating agent, DGN462, are highly potent in vitro and in vivo against human cancer models. Cancer Research. 74(19_Supplement). 2644–2644. 4 indexed citations

17.

Whiteman, Kathleen R., Paul Noordhuis, Yelena Kovtun, et al.. (2014). The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML) with FLT3-ITD Mutations. Blood. 124(21). 2321–2321. 29 indexed citations

18.

Whiteman, Kathleen R., Holly A. Johnson, Alan Wilhelm, et al.. (2013). Abstract C162: Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models.. Molecular Cancer Therapeutics. 12(11_Supplement). C162–C162.

19.

Crackower, Michael A., Lily Y. Moy, Yanlin Jia, et al.. (2012). Characterization of a Novel, Potent and Selective Small Molecule Spleen Tyrosine Kinase (SYK) Inhibitor in In Vitro and In Vivo Models of Asthma.. Journal of Allergy and Clinical Immunology. 129(2). AB49–AB49. 1 indexed citations

20.

Wilhelm, Alan, et al.. (1995). Modulation der zytoplasmatischen Ca²⁺-Konzentration isolierter Myozyten des Detrusor vesicae durch Anticholinergika. Aktuelle Urologie. 26(S 1). 4–6. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact